Can Your Breath Reveal Your Asthma Control? A New Biomarker Shows Promise
"Exhaled breath temperature (EBT) might be the non-invasive monitoring tool you've been waiting for. Find out how this pilot study is changing asthma management."
Asthma, a chronic respiratory disease, is characterized by inflammation and bronchospasm. Monitoring the degree of inflammation has always been challenging. Historically, doctors rely on patient-reported symptoms and recent history, which can be subjective. Those experiencing frequent asthma attacks, nighttime symptoms, or exercise-induced breathing difficulties are generally classified as having uncontrolled asthma.
While methods like bronchoscopy with biopsy can provide direct evidence of bronchial inflammation, they are invasive. There’s a need for objective, non-invasive measurements to track inflammation in asthma patients. Now, emerging research suggests that measuring exhaled breath temperature (EBT) may offer a promising solution.
A pilot study investigated the potential of EBT as a biomarker for asthma control. By exploring this innovative, non-invasive method, the study aimed to determine if EBT could effectively monitor patients with uncontrolled asthma.
Breath Temperature and Asthma Control
Research on fractional exhaled breath temperature has included 65 subjects: 16 with asthma, 18 with chronic obstructive pulmonary disease, 17 with systemic sclerosis, and 14 healthy participants. Another study reported that exhaled breath temperature was higher at hospital admission than one week after discharge, measuring 34.1°C versus 33.6°C. However, a study of asthma control found no significant difference in exhaled breath temperature plateau levels between controlled and not-well-controlled groups; 43 patients were controlled and 26 were not well controlled. These findings suggest that breath temperature may reflect clinical changes, but its relationship with asthma control is not consistent across studies.
A Noninvasive but Inconsistent Signal
One study observed higher exhaled-breath temperature in people with uncontrolled asthma than in those with controlled asthma and healthy controls. A pilot study likewise reported that uncontrolled asthma, especially during exacerbations, was followed by increased exhaled-breath temperature that decreased after asthma control improved. Exhaled-breath condensate collection is described as noninvasive, requiring only tidal breathing, and does not modify airway-surface conditions. Even so, these sources support breath measurements as potentially useful indicators rather than definitive replacements for established clinical assessment.
From Ancient Descriptions to Breath Biomarkers
The earliest cited mention of respiratory distress and wheezing appears in China in 2600 BC, where herbal fumes were reportedly used. Modern clinical descriptions recognize triggers such as pets or pollen, smoke, cold weather, exercise, strong smells, and stress. Later breath-temperature research identified a reported average exhaled-breath temperature of 35.75°C in asthmatic participants, described as 1.30°C higher than a comparison value. Together, these milestones trace asthma understanding from early symptom descriptions toward measurable airway-related signals.
Exhaled Breath Temperature (EBT): A New Way to Monitor Asthma?
The pilot study, conducted at the Federal University of São Paulo, Brazil, involved nine atopic patients diagnosed with uncontrolled asthma. The study excluded individuals with respiratory infections, cardiovascular diseases, or those unable to perform the necessary breathing maneuvers.
- EBT Measurement: A portable exhaled breath collector, similar to a thermos, was used. Patients exhaled repeatedly into the device through a valve mouthpiece for 5-10 minutes until the temperature stabilized.
- Pulmonary Function Test: Spirometry was performed to measure FEV₁ (forced expiratory volume in one second), an indicator of lung function.
- Medication: Patients used inhaled budesonide/formoterol every 12 hours, with additional doses as needed for symptom relief. Severe cases also received oral prednisolone initially.
Recent Results Temper Enthusiasm
A recent report found no significant difference in exhaled-breath temperature between asthmatic participants and healthy subjects. The reported means were 34.54±0.68°C for asthmatics and 34.24±0.51°C for healthy subjects, with p=0.14. The study also reported no association between the measured temperature and its evaluated clinical variables. These results indicate that exhaled-breath temperature may not reliably distinguish asthma from health in every study population.
Biology Does Not Guarantee Precision
Exhaled-breath temperature has been described as reflecting both eosinophilic and neutrophilic airway inflammation in asthma. That biological connection is a reason it may aid asthma management. However, a marker can reflect inflammation without consistently separating levels of asthma control or producing a clinically decisive result. The available source therefore supports potential usefulness while leaving measurement performance and practical reliability as unresolved limitations.
Temperature Differences by Control Level
In one comparison, poorly controlled asthma was associated with an exhaled-breath temperature of 35.00±0.40°C. Well-controlled asthma was associated with a lower value of 34.41±0.69°C, and the difference was reported as statistically significant. This comparison supports the possibility that exhaled-breath temperature can distinguish control groups in some settings. It should be interpreted alongside other studies that reported no significant difference, rather than as a universally established threshold.
The Future of Asthma Monitoring: What EBT Could Mean for You
The study's findings suggest that EBT could serve as a valuable parameter in assessing asthma control. Unlike more invasive methods, EBT measurement is simple, non-invasive, and can potentially provide real-time feedback on airway inflammation.
A Promising but Developing Tool
Exhaled-breath temperature reflects both eosinophilic and neutrophilic airway inflammation and may therefore aid asthma management, including in children. Another source reports that exhaled-breath temperature plateau and exhaled nitric oxide are correlated in children with asthma. Separately, a 2024 exploratory study identified discriminative volatile organic compounds in exhaled breath between bronchial-thermoplasty responders and non-responders at baseline. These findings point toward breath analysis as a developing platform, while not establishing that any single breath marker can guide treatment on its own.
Connecting Biomarkers With Better Control
The CDC describes EXHALE as a set of six strategies designed to facilitate asthma control in children and adults and reduce emergency care. A separate asthma epidemiology forecast projects that severity-specific intermittent asthma cases will surpass other categories by 2034, suggesting a possible shift toward improved asthma severity patterns. A presentation by pediatric pulmonologist Dr. Jered Weinstock highlights trends in asthma care and opportunities for patients. Together, these sources place emerging breath biomarkers within a broader future focused on prevention, monitoring, and improved asthma care.
Control Depends on More Than Measurement
The World Health Organization states that inhaled medication can control asthma symptoms and allow people with asthma to lead normal, active lives. It also identifies avoiding asthma triggers as part of asthma management. Research comparing fractional exhaled breath temperature in asthma, chronic obstructive pulmonary disease, systemic sclerosis, and healthy controls illustrates the challenge of interpreting a signal across different conditions. Severe-asthma resources further describe suboptimal symptom control as having wider implications beyond individual patients.
The Daily Cost of Poor Control
One asthma-management source reports that more than 260 million people globally live with poorly controlled asthma and emphasizes control as important for maintaining quality of life. A case study of a 30-year-old woman with moderate persistent asthma reported fewer asthma attacks and improvement after management. Another case review examined the tests needed to confirm asthma and the environmental factors that can affect control in a young adult with eczema. These examples show why a useful biomarker would need to support practical decisions that matter to patients' symptoms, safety, and daily lives.
While promising, this is just a pilot study with a small sample size. Further research is needed to validate these findings and explore the full potential of EBT in asthma management. Factors such as the device's usability in different age groups need to be addressed for widespread adoption.
For individuals with asthma, EBT monitoring could lead to more personalized and effective treatment strategies. By providing an objective measure of airway inflammation, EBT has the potential to improve asthma control, reduce exacerbations, and enhance overall quality of life.